加载中
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
前收盘价
US$14.91
+US$0.79 · +5.59%
盘中时间采用ET。市场数据可能有所延迟。
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
日内区间
当前US$14.91
52周区间
当前US$14.91
盘中时间采用ET。市场数据可能有所延迟。
Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.
日内区间
当前US$14.91
52周区间
当前US$14.91
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 1084.4万 USD | — | 1万 USD | 7.5万 USD | 115.98万 USD |
| 毛利 | 1084.4万 USD | — | 1万 USD | 7.5万 USD | 115.98万 USD |
| 研究与开发 | 1.38亿 USD | 2806.05万 USD | 2007.17万 USD | 2839.09万 USD | 4749.16万 USD |
| 销售、一般及管理费用 | 2539万 USD | 1632.46万 USD | 1921.3万 USD | 1908.7万 USD | 1711.54万 USD |
| 营业费用 | 1.63亿 USD | 4989.75万 USD | 3928.53万 USD | 4747.83万 USD | 6460.7万 USD |
| 利息收入 | 287.5万 USD | 100.12万 USD | 237.59万 USD | 71.45万 USD | 1.98万 USD |
| 利息支出 | 218.5万 USD | 85.2万 USD | — | — | — |
| 折旧和摊销 | 8.4万 USD | 3.52万 USD | 15.33万 USD | 20.71万 USD | 26.46万 USD |
| 营业利润 | −1.53亿 USD | −4989.75万 USD | −3927.53万 USD | −4740.33万 USD | −6344.72万 USD |
| 净利润 | −1.54亿 USD | −4852.34万 USD | −3689.94万 USD | −4668.88万 USD | −6342.74万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$36.00
上涨空间 141.45%| 行动 | 除息日 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股息 | 2023年1月13日 | US$0.24Quarterly | — | — |
股息 | 2022年9月21日 | US$1.43Annual | — | — |
除息 2023年1月13日
US$0.24
Quarterly
除息 2022年9月21日
US$1.43
Annual
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1505.03万0.00%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM1059.63万0.01%787.4亿 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI475.83万0.05%98.74亿 USD0.35%US$153.77+3.00%
iShares Russell 2000 Growth ETFIWO377.59万0.03%139.17亿 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO205.74万0.01%180亿 USD0.06%US$112.66+0.50%
Vanguard Extended Market ETFVXF139.11万0.00%954亿 USD0.05%US$235+0.80%
iShares Micro-Cap ETFIWC129.82万0.10%13.17亿 USD0.60%US$183+0.11%
Vanguard Health Care ETFVHT103.77万0.00%220亿 USD0.09%US$319.01+1.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCVanguard Health Care ETFVHTAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
